CN113130033A - Application of substance in preparation of product for treating primary dysmenorrhea - Google Patents
Application of substance in preparation of product for treating primary dysmenorrhea Download PDFInfo
- Publication number
- CN113130033A CN113130033A CN201911401018.1A CN201911401018A CN113130033A CN 113130033 A CN113130033 A CN 113130033A CN 201911401018 A CN201911401018 A CN 201911401018A CN 113130033 A CN113130033 A CN 113130033A
- Authority
- CN
- China
- Prior art keywords
- primary dysmenorrhea
- gallic acid
- product
- substance
- capsule
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
- G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
Landscapes
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Medical Informatics (AREA)
- Primary Health Care (AREA)
- Public Health (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
- Cosmetics (AREA)
Abstract
The invention relates to an application of a substance in preparing a product for treating primary dysmenorrhea and a quality control marker for treating primary dysmenorrhea by using a cassia twig and poria cocos capsule. The substance comprises at least one of gallic acid, ethyl gallate, galloyl paeoniflorin, and 1,2,3,4, 6-pentagalloyl glucose. The application comprises the treatment of primary dysmenorrhea and the quality control of the cassia twig and tuckahoe capsule. The inventor carries out calculation prediction analysis by a network pharmacology method and identifies a substance which can inhibit COX2 to play the roles of resisting inflammation, relieving pain and the like so as to treat the primary dysmenorrhea in the cassia twig and poria cocos capsule, so that the group of substances can also be used as quality control markers for interfering COX2 in treating the primary dysmenorrhea. In vitro validation experiments showed that this group of substances was able to inhibit COX2 enzyme activity.
Description
Technical Field
The invention relates to an application of a substance in preparing a product for treating primary dysmenorrhea and a quality control marker for treating primary dysmenorrhea by using a cassia twig and poria cocos capsule.
Background
Primary Dysmenorrhea (PD) refers to non-Primary DysmenorrheaA functional meridian pain caused by genital organ organic lesion seriously affects normal work and life quality of patients[1]. Currently, non-steroidal anti-inflammatory drugs (NSAIDs) are administered clinically at regular doses as first-line drugs for the treatment of primary dysmenorrhea. NSAIDs are used for treating dysmenorrhea by inhibiting Cyclooxygenase (COX) to reduce synthesis of Prostaglandins (PGs) and further reduce uterine spasmodic contraction caused by PGs[2]. Wherein, cyclooxygenase 2(COX2) is the main intervention target of the first-line medicament for treating primary dysmenorrhea. NSAIDs are mainly used for relieving pain symptoms during dysmenorrhea attack, have no obvious effect on preventing the attack, shortening the attack days and the like, and are easy to cause a plurality of adverse reactions such as gastrointestinal side effects and the like after long-term administration.
The cassia twig and tuckahoe capsule is originated from classic famous prescription of golden starvation, woman pregnancy syndrome and treatment, is composed of five traditional Chinese medicines of cassia twig, tuckahoe, tree peony bark, white paeony root and peach kernel, and has the efficacies of promoting blood circulation to remove blood stasis, eliminating stagnation and eliminating mass[3]. The cassia twig and tuckahoe capsule contains a plurality of components, and mainly comprises monoterpene and glycosides thereof, triterpene and glycosides thereof, flavonoids, organic acids, phenol and phenol glycosides and other components[4]The traditional Chinese medicine composition is mainly applied to the treatment of gynecological diseases such as hysteromyoma, pelvic inflammation, dysmenorrhea, endometriosis, ovarian cyst and hyperplasia of mammary glands in clinic. How to identify effective components for interfering COX2 to treat primary dysmenorrhea and quality control markers thereof from a plurality of components of the Guizhi Fuling Capsule is a problem to be solved when the Guizhi Fuling Capsule is widely used clinically at present.
Disclosure of Invention
The network pharmacology-based 'network target-system regulation' research mode can comprehensively and systematically describe the association of the traditional Chinese medicine components and the disease-evidence biomolecules in a biological network form, establish a network target model, and further analyze the action mechanism of the traditional Chinese medicine components and predict the intervention result of the disease symptoms on the basis of the network target. The research mode of 'network target-system regulation' based on network pharmacology is more consistent with the essence of a biological system, and the limitation that the research of drugs and diseases is disjointed can be overcome[5]Also provides a new idea for the clinical research of the traditional Chinese medicine[6]. The research mode of network target-system regulation is well applied to the explanation of the action mechanism of the traditional Chinese medicine prescription and the natural medicine[7-8]。
The inventor discovers that the target spectrum of the cassia twig and poria cocos capsule compound is obviously enriched in biological processes such as inflammatory reaction, pain perception and the like through network pharmacological analysis based on 'network target-system regulation' on the cassia twig and poria cocos capsule compound, and identifies a substance which can intervene the main treatment target of primary dysmenorrhea, namely a key enzyme COX2 in inflammation and pain, and plays an anti-inflammatory and analgesic role so as to treat the primary dysmenorrhea in the cassia twig and poria cocos capsule compound, so that the substance group can also be used as a quality control marker for the cassia twig and poria cocos capsule intervention COX2 to treat the primary dysmenorrhea. In vitro validation experiments showed that this group of substances was able to inhibit COX2 enzyme activity.
According to one aspect of the present invention, there is provided a use of a substance as a product for the treatment of primary dysmenorrhea, wherein the product is one selected from the group consisting of a pharmaceutical product and a health product, the substance comprising at least one component selected from the group consisting of:
a gallic acid, wherein the gallic acid is contained in the water,
the content of the gallic acid ethyl ester is,
the galloyl paeoniflorin is prepared by the steps of,
1,2,3,4, 6-pentagalloylglucose.
According to another aspect of the present invention, there is provided a use of a substance as a quality control marker for the treatment of primary dysmenorrhea in a Guizhi Fuling Capsule, wherein the substance comprises at least one ingredient selected from the following ingredients:
a gallic acid, wherein the gallic acid is contained in the water,
the content of the gallic acid ethyl ester is,
the galloyl paeoniflorin is prepared by the steps of,
1,2,3,4, 6-pentagalloylglucose.
According to a further aspect of the present invention, there is provided a product characterized in that it has as an active ingredient at least one selected from the following:
a gallic acid, wherein the gallic acid is contained in the water,
the content of the gallic acid ethyl ester is,
the galloyl paeoniflorin is prepared by the steps of,
1,2,3,4, 6-pentagalloylglucose,
and other auxiliary materials, wherein the product is one selected from medicines and health care products.
According to a further aspect of the present invention, the dosage form of the pharmaceutical product and the health product is one selected from the group consisting of tablets, capsules, pills, injections, sustained-release agents, controlled-release agents, powders, beverages and the like.
Drawings
Fig. 1 is a flow chart of computational analysis of Guizhi Fuling Capsule for treating primary dysmenorrhea based on cyber pharmacological discovery according to an embodiment of the present invention.
Fig. 2 is a primary dysmenorrhea related molecular network modulated by cinnamomi poria capsule compounds according to one embodiment of the present invention.
Fig. 3 is an illustrative diagram of a cybergology-based Guizhi Fuling capsule compound target spectral clustering analysis according to an embodiment of the present invention.
Fig. 4A to 4D are experimental verification graphs of the inhibition of enzymatic activity of COX2, a key enzyme in inflammation and pain, by a part of the ingredients of the cinnamomi poria capsule according to one embodiment of the present invention.
Detailed Description
The inventor discovers that the cassia twig and poria cocos capsule compounds such as gallic acid, ethyl gallate, galloyl paeoniflorin and 1,2,3,4, 6-pentagalloyl glucose can intervene in primary dysmenorrhea, and the main treatment target COX2 plays a role in resisting inflammation and relieving pain so as to treat the primary dysmenorrhea by performing target prediction and biological function enrichment analysis on the cassia twig and poria cocos capsule compounds. Furthermore, in vitro experimental studies prove that the cassia twig and poria cocos capsule compounds such as gallic acid, ethyl gallate, galloyl paeoniflorin and 1,2,3,4, 6-pentagalloyl glucose can inhibit COX2 enzyme activity.
The inventor carries out a series of network pharmacology calculation prediction analysis and experimental verification. The network pharmacology analysis flow is shown in figure 1. The work performed by the present inventors includes:
(1) cassia twig and poria cocos capsule compound target prediction based on network pharmacology
The inventor adopts a high-precision drug target prediction method to carry out target spectrum prediction on the cassia twig and poria cocos capsule compound collected in the literature.
(2) Cassia twig and poria cocos capsule compound target spectrum biological function enrichment analysis based on network pharmacology
The inventor utilizes enrichment analysis to calculate the biological function influenced by the cassia twig and tuckahoe capsule compound. Targets for each component are enriched with the Gene set for each entry of the Gene ontology Biological process (GO BP). In order to reflect a more specific biological process, the enrichment result reserves GO BP items of 4-6 levels.
(3) Cassia twig and poria cocos capsule compound target spectrum clustering analysis based on network pharmacology
The inventor simultaneously predicts a target spectrum for the cassia twig and poria cocos capsule compound and the existing non-steroidal anti-inflammatory drug for first-line treatment of primary dysmenorrhea, and performs maximum distance hierarchical clustering analysis based on related distances by using the predicted target spectrum.
(4) Experimental verification shows that substances for inhibiting COX2 activity in Guizhi Fuling capsules
The inventor adopts a biological evaluation method based on fluorescence detection of the activity of the humanized recombinant COX2 enzyme to detect a substance which inhibits the activity of COX2 in the cassia twig and poria cocos capsule. The technology detects the influence of the cassia twig and poria cocos capsule compound on the effect of COX2 according to the specification of a cyclooxygenase 2(COX2) inhibitor screening kit.
Example 1: the calculation and prediction of the treatment of the primary dysmenorrhea, which is a drug effect substance in the cassia twig and tuckahoe capsules for treating the primary dysmenorrhea, are related to anti-inflammation and analgesia. The inventor identifies the drug effect substance for treating primary dysmenorrhea in the cassia twig and poria cocos capsule through network pharmacology calculation prediction, and the method comprises the following steps:
1. cassia twig and poria cocos capsule compound collection
The cassia twig-tuckahoe capsule comprises 5 traditional Chinese medicines of cassia twig, tuckahoe, tree peony bark, white paeony root and peach kernel, and compounds reported in the cassia twig-tuckahoe capsule part are collected from the literature. The number of compounds contained in each herb is shown in Table 1.
TABLE 1 information of the compounds of the Chinese herbs contained in Guizhi Fuling Jiaonang
| Chinese medicine | Number of compounds | Primary references |
| Ramulus Cinnamomi | 30 | [9] |
| Poria cocos (Schw.) wolf | 33 | [9] |
| Cortex moutan | 66 | [9] |
| White peony root | 57 | [9] |
| Peach kernel | 28 | [9] |
2. Compound target prediction
In the invention, the inventor uses a high-precision compound target prediction algorithm to calculate and predict the target spectrum of the direct action or indirect action of the compound in the cassia twig and poria cocos capsule. The algorithm is independently developed for systematic prediction of Chinese medicine compound targets and network relation analysis of the targets, the relation strength of a given compound and the targets is predicted by using the overall correlation information of big data, and the modular construction principle of a 'medicine-molecule-disease' global network is disclosed, so that the large-scale and whole-genome target prediction of medicines (Chinese medicine components) is realized by efficiently using modern medical life science data and network modularity rules. The method utilizes a regression model to depict the overall association of a chemical space and a whole genome space of a drug, integrates the association of a given traditional Chinese medicine compound and an FDA drug and the association of a known target of the FDA drug on a PPI network, and provides a target spectrum containing a direct target and an indirect target.
3. The method for analyzing the enrichment of biological function modules by the aid of the cassia twig and poria cocos capsule compound target spectrum biological function enrichment based on network pharmacology is characterized in that the correlation between a compound prediction target spectrum and a known biological process is represented by the enrichment degree of the compound prediction target spectrum and a known functional gene set, and if the compound prediction target spectrum and the known functional gene set are significantly enriched, the fact that the corresponding compound prediction target spectrum and the biological process have a strong correlation is shown. The inventor utilizes enrichment analysis to calculate the biological function influenced by the cassia twig and tuckahoe capsule compound. The targets of each component were enriched with each Gene set in the Gene integration Biological Process (GO BP) entries. In order to reflect a more specific biological process, the enrichment result reserves GO BP items of 4-6 levels. The inventor finds that the biological processes of significantly enriching the target spectrum of the cassia twig and poria cocos capsule compound have inflammatory reaction, pain perception and the like. The network of reported compound-regulated primary dysmenorrhea related molecules of the Guizhi Fuling Capsule part constructed based on network target analysis is shown in figure 2. The cassia twig and poria cocos capsule compounds are found to predict that target molecules COX2, CNR1, CNR2, IL12B, OPRM1, F2R and ADCYAP1 are all related to inflammatory response and pain perception biological processes at the same time, and COX2 is a key molecule for first-line treatment of primary dysmenorrhea drug non-steroidal anti-inflammatory drug intervention.
4. Based on the target spectrum clustering analysis of the cassia twig and poria cocos capsule compound, a substance possibly interfering with COX2 is discovered
The inventor simultaneously predicts a target spectrum of main compounds contained in the cassia twig and poria cocos capsules and the existing non-steroidal anti-inflammatory drug for first-line treatment of primary dysmenorrhea. In order to determine the ingredients of the Guizhi Fuling Capsule for interfering COX2 to treat primary dysmenorrhea, a total of 6 non-steroidal anti-inflammatory drugs (NSAIDs) approved by FDA to treat primary dysmenorrhea were collected, including Ibuprofen, ketoprofen, Meclofenamic acid, Diclofenac, Mefenamic acid, Naproxen, and maximum distance hierarchical clustering analysis was performed to determine the potential ingredients for treating primary dysmenorrhea by calculating the target spectra of the compounds contained in the Guizhi Fuling Capsule and non-steroidal anti-inflammatory drugs (NSAIDs), so as to obtain 7 substances possibly interfering COX2 to exert anti-inflammatory and analgesic effects in the Guizhi Fuling Capsule, wherein the group of substances mainly includes gallic acid, ethyl gallate, galloyl paeoniflorin, 1,2,3,4, 6-pentagalloyl glucose, paeonol, cinnamaldehyde and cinnamic acid, as shown in FIG. 3.
Example 2: compound in Guizhi Fuling capsule for inhibiting COX2 enzyme activity 1. experiment method
Based on 7 substances (including gallic acid, ethyl gallate, galloyl paeoniflorin, 1,2,3,4, 6-pentagalloyl glucose, paeonol, cinnamaldehyde and cinnamic acid) which are predicted and discovered by calculation and possibly interfere with COX2, the invention carries out an experiment that the compounds inhibit the activity of COX2 enzyme. The study on the activity of the compound in the cassia twig and poria cocos capsules for inhibiting COX2 is carried out by adopting a biological evaluation method based on fluorescence detection of humanized recombinant COX-2 enzyme activity. The experimental materials include 96-well cell plate (Corning 3925black plate, black bottom), and cyclooxygenase-2
(COX-2) inhibitor screening kit, Picris japonica (Item No. S0168) and gallic acid (No. 307, gallic acid,149-91-7), ethyl gallate (No. 442, ethyl gallate,831-61-8), galloyl paeoniflorin (No. 443, galloyl paeoniflorin, 122965-41-7), 1,2,3,4, 6-pentagalloyl glucose (No. 441, 1,2,3,4,6-O-pentagalloyl glucose,14937-32-7), paeonol (number: 059, paeonol,552-41-0), Cinnamic acid (number: 440, Cinnamic acid, 140-10-3|621-82-9), and Cinnamaldehyde (number: 439, Cinnanaldehyde, 14371-10-9| 104-55-2).
Dissolving seven pure compounds of gallic acid, ethyl gallate, galloyl paeoniflorin, 1,2,3,4, 6-pentagalloyl glucose, paeonol, cinnamaldehyde and cinnamic acid in DMSO, preparing into required concentration, and performing subsequent sample detection. Unfreezing the enzyme to normal temperature, centrifuging and mixing uniformly for later use; probe, Cofactor (50X), and Substrate (50X) in DMSO, thawing (water bath at 37 deg.C for 0.5-2min) to room temperature, and storing in dark (long-term-20 deg.C in dark). Cofactor working fluid: an appropriate amount of Cofactor (50X) was diluted 50-fold with assay buffer and stored at 4 ℃ for use on the day. COX-2 working solution: an appropriate amount of rhCOX-2 (25X) was diluted 25-fold with the assay buffer and stored in ice bath for 1 h. Substrate working solution: appropriate amount of Substrate (50X), diluting with equal volume of Substrate buffer, mixing by vortex, diluting the mixture with ultrapure water by 125 times, and storing in ice bath for 1 h. Preparing positive drugs: an appropriate amount of Celecoxib (CEX) at 100 μ M was diluted with DMSO to 0.9 μ M for use. Arranging according to each hole, adding the assay buffer, the Cofactor working solution (oscillation), the COX-2 working solution (oscillation) and the sample solution, discharging the mixture, uniformly mixing, and incubating for 5min at 25 ℃; when the discharging guns are mixed evenly, the volume of the discharging guns is adjusted to 40ul, and the discharging guns are continuously blown and beaten for three times each time, and the last liquid is discharged at the last time and hung on the liquid level. Then putting the mixture on ice for incubation for 10min, and cooling; adding 5 mul of Probe working solution into each hole, and uniformly mixing the solution in a gun arrangement manner; adding 5 mul of low-temperature Substrate working solution into each hole, operating at low temperature as much as possible, arranging guns and mixing uniformly; adding working solution, mixing, incubating at 37 deg.C for 15min, and immediately measuring fluorescence (RFU), excitation wavelength is 560nm, and emission wavelength is 590 nm. Using the curve fitting tool of GraphPad Prism software, selecting "log { inhibit } vs. respond-Variable slope { four parameter } in the" Dose-response-inhibit "option, then" setting the limits "lower limit (Bottom)" and "upper limit (Top)" in the numerical limits (constraints) "to" greater than 0 "and" less than 100 ", respectively, plotting a quantity-effect curve, predicting IC50, and, in the case of GraphPad Prism software already installed in the computer, double-clicking the graphs herein, one can see the relative enzyme activity and the corresponding concentration.
2. Results of the experiment
Experimental results show that gallic acid,1, 2,3,4, 6-pentagalloylglucose, ethyl gallate and galloyl paeoniflorin all have good inhibitory activity on COX-2, while paeonol, cinnamaldehyde and cinnamic acid have no inhibitory activity on COX 2. On the basis of this, further examination of the amount-effect of 4 active compounds revealed that gallic acid IC50 was 35.15. mu.M (5.9797. mu.g/ml), 1,2,3,4, 6-pentagalloylglucose IC50 was 6.926. mu.M (6.5148. mu.g/ml), ethyl gallate IC50 was 19.97. mu.M (3.9574. mu.g/ml), and galloyl paeoniflorin IC50 was 13.3. mu.M (8.4124. mu.g/ml), respectively. The dose-effect curves of gallic acid,1, 2,3,4, 6-pentagalloylglucose, ethyl gallate and galloyl paeoniflorin for inhibiting COX2 activity are shown in FIGS. 4A-4D. The results indicate that part of the components of the cassia twig and poria cocos capsule can influence the expression and activity of a key enzyme COX2 in inflammation and pain, further influence the synthesis of Prostacyclin (PGs) in uterus, play an anti-inflammatory and analgesic role and improve primary dysmenorrhea. Therefore, the gallic acid, the 1,2,3,4, 6-pentagalloylglucose, the ethyl gallate and the galloylpaeoniflorin can be used as quality control markers of the cassia twig and poria cocos capsule for treating primary dysmenorrhea to a certain extent.
Reference
[1]Burnett M,Lemyre M.No.345-Primary Dysmenorrhea Consensus Guideline[J].Journal of Obstetrics and Gynaecology Canada,2017,39(7):585-595.
[2] Study progress of therapeutic drugs and therapeutic targets for treating primary dysmenorrhea [ J ] in Chile Xiao Li, Liu national cloud, Wenxxia, Zhang Yongxiang, Liu super ] in Acad of military medicine, 2007(05): 470-.
[3] The medicine for treating primary dysmenorrhea is characterized by using the Chinese medicinal materials of chenchenjing, Song Dynasty Rong, Zhangliu, Guo, Weiluo, Pagli, Wang Xiao Gui Fuling capsule as raw material and adopting Meta analysis of primary dysmenorrhea therapeutic effect [ J ]. Hunan J.T. 2019,35(08): 126-.
[4] Zhang Li Ye, Tian Cheng Wang, Liu Su Xiang, etc. the predictive analysis of the chemical components, pharmacological actions and quality markers (Q-marker) of the Guizhi Fuling Fang (J) Chinese herbal medicine, 2019,50(02):6-13.
[5]Li S.Mapping ancient remedies:Applying a network approach to traditional Chinese medicine. Science 2015,350(6262Suppl):S72-S74.
[6]Li S,Zhang B,Zhang N.Network target for screening synergistic drug combinations with application to traditional Chinese medicine.BMC Syst Biol 2011,5Suppl 1:S10.
[7]Liang X,Li H,Li S.A novel network pharmacology approach to analyse traditional herbal formulae:the Liu-Wei-Di-Huang pill as a case study.Mol Biosyst 2014,10(5):1014-1022.
[8]Zhang B,Lu C,Bai M,He X,Tan Y,Bian Y,Xiao C,Zhang G,Lu A,Li S. Tetramethylpyrazine identified by a network pharmacology approach ameliorates methotrexate-induced oxidative organ injury.J Ethnopharmacol 2015,175:638-647.
[9] The former phytochemistry of traditional Chinese medicine is divided into [ M ] and [ 2009 ] scientific press.
Claims (5)
1. Use of a substance for the preparation of a product for the treatment of primary dysmenorrhea, wherein:
the product is one selected from the following:
the dosage of the medicine is controlled by the control system,
a health-care food is prepared from the Chinese-medicinal materials,
the substance comprises at least one component selected from the following components:
a gallic acid, wherein the gallic acid is contained in the water,
the content of the gallic acid ethyl ester is,
galloyl paeoniflorin, and
1,2,3,4, 6-pentagalloylglucose.
2. A product characterized in that it comprises as active ingredient of the product at least one ingredient selected from the group consisting of:
a gallic acid, wherein the gallic acid is contained in the water,
the content of the gallic acid ethyl ester is,
the galloyl paeoniflorin is prepared by the steps of,
1,2,3,4, 6-pentagalloylglucose,
wherein the product is one selected from medicines and health products.
3. The product according to claim 2, wherein the product is for the treatment of primary dysmenorrhea.
4. The product according to any one of claims 2 and 3, wherein the pharmaceutical and/or nutraceutical is in the form of one selected from the group consisting of tablets, capsules, pills, injections, sustained release formulations, controlled release formulations, powders, beverages and the like.
5. Use of a substance as a quality control marker for the treatment of primary dysmenorrhea in a Guizhi Fuling Capsule, wherein said substance comprises at least one component selected from the group consisting of:
a gallic acid, wherein the gallic acid is contained in the water,
the content of the gallic acid ethyl ester is,
galloyl paeoniflorin, and
1,2,3,4, 6-pentagalloylglucose.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911401018.1A CN113130033A (en) | 2019-12-30 | 2019-12-30 | Application of substance in preparation of product for treating primary dysmenorrhea |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911401018.1A CN113130033A (en) | 2019-12-30 | 2019-12-30 | Application of substance in preparation of product for treating primary dysmenorrhea |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN113130033A true CN113130033A (en) | 2021-07-16 |
Family
ID=76768235
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201911401018.1A Pending CN113130033A (en) | 2019-12-30 | 2019-12-30 | Application of substance in preparation of product for treating primary dysmenorrhea |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113130033A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114404437A (en) * | 2022-03-15 | 2022-04-29 | 山东中医药大学 | Application of galloyl paeoniflorin in preparation of GABAA receptor inhibitor |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102759509A (en) * | 2011-04-25 | 2012-10-31 | 江苏康缘药业股份有限公司 | Detection method of cassiabarktree twig tuckahoe capsules |
| CN110531076A (en) * | 2019-07-19 | 2019-12-03 | 江苏康缘药业股份有限公司 | A method of COX-2 enzymatic activity in detection medicine analgesic evaluation procedure |
-
2019
- 2019-12-30 CN CN201911401018.1A patent/CN113130033A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102759509A (en) * | 2011-04-25 | 2012-10-31 | 江苏康缘药业股份有限公司 | Detection method of cassiabarktree twig tuckahoe capsules |
| CN110531076A (en) * | 2019-07-19 | 2019-12-03 | 江苏康缘药业股份有限公司 | A method of COX-2 enzymatic activity in detection medicine analgesic evaluation procedure |
Non-Patent Citations (4)
| Title |
|---|
| SIQIN ZHANG等: ""Deciphering the Pharmacological Mechanisms of Guizhi-Fuling Capsule on Primary Dysmenorrhea Through Network Pharmacology"", FRONTIERS IN PHARMACOLOGY, vol. 12, pages 10 * |
| 尹权微 等: ""UPLC/Q-TOF-MS快速分析桂枝茯苓胶囊的入血成分"", 中国实验方剂学杂志, vol. 22, no. 21, pages 84 * |
| 王运来 等: ""基于生物网络的当归芍药散、桂枝茯苓丸治疗原发性痛经作用机制研究"", 中药材, vol. 38, no. 11, pages 2348 * |
| 陶晓倩 等: ""桂枝茯苓胶囊中主要成分对人子宫肌瘤细胞增殖及小鼠离体子宫收缩活动的影响"", 中国实验方剂学杂志, vol. 22, no. 2, pages 91 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114404437A (en) * | 2022-03-15 | 2022-04-29 | 山东中医药大学 | Application of galloyl paeoniflorin in preparation of GABAA receptor inhibitor |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Wang et al. | Ethanol extract from a Chinese herbal formula,“Zuojin Pill”, inhibit the expression of inflammatory mediators in lipopolysaccharide-stimulated RAW 264.7 mouse macrophages | |
| Dou et al. | Chrysophanol ameliorates renal interstitial fibrosis by inhibiting the TGF-β/Smad signaling pathway | |
| Pan et al. | Traditional Chinese medicine as a treatment for rheumatoid arthritis: From empirical practice to evidence-based therapy | |
| Wang et al. | Systems pharmacology dissection of multiscale mechanisms of action for herbal medicines in treating rheumatoid arthritis | |
| Chen et al. | A novel compound AB-38b improves diabetes-associated cognitive decline in mice via activation of Nrf2/ARE pathway | |
| Li et al. | Deciphering the multicomponent synergy mechanisms of SiNiSan prescription on irritable bowel syndrome using a bioinformatics/network topology based strategy | |
| Xiong et al. | Traditional Chinese medicine suppresses left ventricular hypertrophy by targeting extracellular signal-regulated kinases signaling pathway in spontaneously hypertensive rats | |
| Shao et al. | The efficacy of Danshen injection as adjunctive therapy in treating angina pectoris: a systematic review and meta-analysis | |
| Yu et al. | A network pharmacology-based study on the mechanism of astragaloside IV alleviating renal fibrosis through the AKT1/GSK-3β pathway | |
| Ding et al. | Antihypertensive activity of Eucommia ulmoides oliv: male flower extract in spontaneously hypertensive rats | |
| Ma et al. | Network pharmacology-based strategy for predicting active ingredients and potential targets of coptis chinensis franchin polycystic ovary syndrome | |
| Tang et al. | A narrative review of COVID-19: magnesium isoglycyrrhizinate as a potential adjuvant treatment | |
| CN113130033A (en) | Application of substance in preparation of product for treating primary dysmenorrhea | |
| Sidhu et al. | Synergistic anti-cancer action of salicylic acid and cisplatin on HeLa cells elucidated by network pharmacology and in vitro analysis | |
| Shao et al. | Sodium tanshinone ⅡA sulfonate injection as adjunctive therapy for the treatment of heart failure: A systematic review and meta-analysis | |
| Sun et al. | Network pharmacology integrated with experimental validation revealed the mechanism of Fengshi Gutong Capsule in the treatment of osteoarthritis | |
| Xu et al. | Discovery and identification of quality markers of Sparganii Rhizoma based on zebrafish thrombosis model | |
| Kameshwari et al. | Urginea indica and its role in psoriasis: A Review. | |
| Chen et al. | Cardioprotective effect of Danhong injection against myocardial infarction in rats is critically contributed by MicroRNAs | |
| Wang et al. | Analysis of common and characteristic actions of Panax ginseng and Panax notoginseng in wound healing based on network pharmacology and meta-analysis | |
| Liu et al. | Mitochondrion-NLRP3 inflammasome activation in macrophages: A novel mechanism of the anti-inflammatory effect of Notopterygium in rheumatoid arthritis treatment | |
| Yu et al. | To explore the mechanism and equivalent molecular group of radix astragali and semen lepidii in treating heart failure based on network pharmacology | |
| CN105963500A (en) | Traditional Chinese medicine preparation for treating cold as well as preparation method and detection method thereof | |
| CN100415259C (en) | Medicine for treating coronary heart disease and preparation thereof | |
| CN102228521A (en) | New Chinese medicine for treating early and middle-stage diabetic nephropathy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |